Background: There are limited data regarding short- and medium-term IgG antibody levels after the CoronaVac and BNT162b2 vaccines. This study aimed to investigate the antibody responses of health workers who initially received two doses of CoronaVac one month apart followed by a booster dose of either CoronaVac or BNT162b2, as well as determine whether either vaccine provided superior results.

Methods: This research represents the second phase of a mixed-methods vaccine cohort study and was conducted between July 2021 and February 2022. The participants (n = 117) were interviewed in person and blood samples were collected before and at 1 and 6 months after the booster vaccination.

Results: BNT162b2 was found to have greater immunogenic potential than CoronaVac ( < 0.001). Health workers without chronic disease exhibited statistically significant increases in antibody levels after both vaccines ( < 0.001), whereas only BNT162b2 caused a significant increase in antibody levels in participants with chronic disease ( < 0.001). Samples obtained before and at 1 and 6 months after the booster vaccination revealed no age- or sex-based differences in IgG-inducing potential for either vaccine ( > 0.05). Antibody levels were comparable in both vaccine groups before the booster regardless of COVID-19 history ( > 0.05); however, antibody levels were significantly higher after the BNT162b2 booster at 1 month (<0.001) and at 6 months, except among participants who had a positive history of COVID-19 infection ( < 0.001).

Conclusions: Our results suggest that even a single booster dose of BNT162b2 after initial vaccination with CoronaVac provides a protective advantage against COVID-19, especially for risk groups such as health workers and those with chronic diseases.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10223587PMC
http://dx.doi.org/10.3390/vaccines11050935DOI Listing

Publication Analysis

Top Keywords

antibody levels
20
coronavac bnt162b2
8
health workers
8
months booster
8
chronic disease
8
005 antibody
8
booster
6
levels
6
antibody
6
vaccine
5

Similar Publications

Graves' disease diagnosed nearly six months after microwave ablation of benign thyroid nodules: a case report.

BMC Endocr Disord

January 2025

Department of Endocrine and Metabolic Diseases, The First People's Hospital of Changzhou, The Third Affiliated Hospital of Soochow University, No. 185, Juqian Street, Changzhou, 213000, Jiangsu, China.

Background: Microwave ablation is a new, minimally invasive technique for the treatment of thyroid nodules. Hyperthyroidism due to destructive thyroiditis is a known risk of microwave ablation, though it occurs in only a minority of cases. We report a rare case of a patient diagnosed with Graves' disease nearly six months after undergoing microwave ablation of a thyroid nodule.

View Article and Find Full Text PDF

Background: Infectious episodes contribute to morbidity and mortality in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Renal involvement, also known as ANCA-associated glomerulonephritis (AGN), is frequently observed in AAV. Little is known about whether co-infection at initial diagnosis is associated with renal outcome and prognosis in children with AGN.

View Article and Find Full Text PDF

Japanese encephalitis virus (JEV) is the leading cause of viral encephalitis in the Asia-Pacific region. Amplification of JEV in pigs is a potent driver for spillover of the infection to humans, and hence monitoring of virus dynamics in pigs can provide insights into JEV ecology. To study the dynamics of natural JEV infection in a tropical region, two groups of immunologically naïve pigs consisting of six animals per group were kept as sentinels on two different farms in the district of Thanjavur, Tamil Nadu, India.

View Article and Find Full Text PDF

Kawasaki disease (KD) is a leading cause of acquired heart disease in children, often resulting in coronary artery complications such as dilation, aneurysms, and stenosis. While intravenous immunoglobulin (IVIG) is effective in reducing immunologic inflammation, 10-15% of patients do not respond to initial therapy, and some show resistance even after two consecutive treatments. Predicting which patients will not respond to these two IVIG treatments is crucial for guiding treatment strategies and improving outcomes.

View Article and Find Full Text PDF

Anti-PD-1 exacerbates bleomycin-induced lung injury in mice via Caspase-3/GSDME-mediated pyroptosis.

Cell Death Dis

January 2025

State Key Laboratory of Respiratory Diseases, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Department of Pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510120, China.

Immune checkpoint inhibitors (ICIs) have significant therapeutic effects but can also cause fatal lung injury. However, the lack of mouse animal models of ICI-related lung injury (ICI-LI) has limited the in-depth exploration of its pathogenesis. In clinical practice, underlying lung diseases increase the risk of lung injury.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!